从资金流向上来看，当日生物制品板块主力资金净流入1.91亿元，游资资金净流出2.73亿元，散户资金净 流入8203.94万元。生物制品板块个股资金流向见下表： | 代码 | 名称 | 主力净流入(元) | 主力净占比 游资净流入(元) | | 游资净占比 散户净流入 (元) | | 散户净占比 | | --- | --- | --- | --- | --- | --- | --- | --- | | 002773 康弘药业 | | 1.18 Z | 18.31% | -3021.77万 | -4.70% | -8748.13万 | -13.61% | | 000661 | 长春高新 | 7444.34万 | 9.43% | -4755.38万 | -6.02% | -2688.95万 | -3.40% | | 688331 荣昌生物 | | 6982.31万 | 10.14% | -2366.87万 | -3.44% | -4615.43万 | -6.71% | | 300122 智飞生物 | | 3724.35万 | 9.83% | 85.58万 | 0.23% | -3809.93万 | -10.05% ...

每经AI快讯，智飞生物1月5日晚间发布公告称，重庆智飞生物制品股份有限公司（以下简称"公司"）近 日接到公司控股股东、实际控制人蒋仁生先生的通知，获悉蒋仁生先生所持有本公司的部分股份解除质 押，本次解除质押股份数量为6545万股。截至本公告日，蒋仁生累计质押股数约为1.19亿股，合计占其 所持股份比例为10.28%。 （记者 曾健辉） 每经头条（nbdtoutiao）——秒光！1499元飞天茅台上线即空，i茅台App冲上苹果购物榜第一，10万用 户已下单！经销商同价做回馈，1000箱很快卖完 ...

1、本次股份解除质押基本情况 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 重庆智飞生物制品股份有限公司（以下简称"公司"）近日接到公司控股股 东、实际控制人蒋仁生先生的通知，获悉蒋仁生先生所持有本公司的部分股份解 除质押，具体事项如下： 一、本次解除质押的基本情况 | | 是否为 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | | 控股股 | | 占其 | 占公 | | | | | 股东 | 东或第 | 本次解除 | 所持 | 司总 | | | | | 名称 | 一大股 | 质押股数 | 股份 | 股本 | 起始日 | 解除日期 | 质权人 | | | 东及其 | （股） | 比例 | 比例 | | | | | | 一致行 | | （%） | （%） | | | | | | 动人 | | | | | | | | | | | | | | | 重庆农村商业 | | 蒋仁生 | 是 | 65,450,000 | 5.64 | 2.73 | 2018-05-28 | 2025-12 ...

关于公司申请银团贷款暨子公司及公司关联方提供担保的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 重庆智飞生物制品股份有限公司（以下简称"公司"）于 2025 年 12 月 31 日召开第六届董事会第九次会议，审议通过《关于公司申请银团贷款暨子公司及 公司关联方提供担保的议案》，并与中国农业银行股份有限公司重庆江北支行作 为牵头行的银团签订了银团贷款协议，具体情况如下： 证券代码：300122 证券简称：智飞生物 公告编号：2026-02 重庆智飞生物制品股份有限公司 3、本次银团贷款担保方式为信用，并追加如下保证，质押，抵押：(1)蒋仁 生及其配偶，蒋凌峰及其配偶，智飞绿竹、智飞龙科马等子公司提供全额连带责 任保证担保。(2)上市公司以应收账款及所持智飞绿竹、智飞龙科马等子公司的 全部股权提供担保。(3)上市公司、智飞绿竹、智飞龙科马等子公司以其工业厂 房，办公楼及在建工程等提供担保。 4、上述银团贷款的具体参贷行、贷款金额、贷款期限、担保方式及条款内 容以各方最终签订的合同为准。 5、公司本次融资事项在股东会已审批的融资额度范围内，且公司以自身资 产 ...

本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 重庆智飞生物制品股份有限公司 第六届董事会第九次会议决议公告 1、本次董事会于 2025 年 12 月 31 日以专人送达的方式向董事发出通知。 2、本次会议于 2025 年 12 月 31 日 14:00 在公司会议室以现场结合通讯方式 召开。 3、本次会议应出席并参加表决的董事 9 人，实际出席并参加表决的董事 9 人。 证券代码：300122 证券简称：智飞生物 公告编号：2026-01 化公司债务结构，补充日常营运资金，加速推进研发项目进展，促进公司稳健经 营与发展。公司实际控制人蒋仁生先生及其配偶、其子蒋凌峰先生及其配偶为公 司本次融资提供无偿担保，构成关联交易。本次关联交易系公司关联方为了促进 公司稳健经营发展为公司融资提供的无偿担保，不存在侵害公司及其他非关联股 东特别是中小股东利益的情形。 具体内容详见公司发布在中国证监会指定信息披露网站巨潮资讯网的《关于 公司申请银团贷款暨子公司及公司关联方提供担保的公告》（2026-02）。 4、本次会议由公司董事长蒋仁生先生主持。 5 ...

Core Viewpoint - Chongqing Zhifei Biological Products Co., Ltd.'s subsidiary, Chongqing Chanan Biopharmaceutical Co., Ltd., has successfully completed the phase III clinical trial for CA508 injection, a dual insulin product for treating type 2 diabetes, demonstrating efficacy and safety comparable to the original drug [1][2]. Product Development Progress and Market Path - Following the completion of the phase III clinical trial, Chongqing Chanan Biopharmaceutical Co., Ltd. will submit a drug production registration application to the National Medical Products Administration, which must pass technical review and clinical site inspection before market approval [2]. - The successful development of CA508 injection signifies a significant breakthrough for Chongqing Chanan Biopharmaceutical Co., Ltd. in the diabetes treatment sector, with broad clinical application prospects [2]. Impact on Company Business Layout - Chongqing Zhifei Biological Products Co., Ltd. indicated that CA508 injection will not have a major short-term impact on overall company performance, but successful market approval could strengthen the company's treatment segment within its integrated "prevention & treatment" business layout [3]. - The strategic extension into therapeutic drugs, particularly in diabetes treatment, reflects the company's commitment to diversifying beyond its traditional vaccine business, laying a solid product foundation for long-term development [3].

Core Insights - The Chongqing Private Economy Innovation and Development Conference recognized Zhifei Biological Products Co., Ltd. for its outstanding performance in technological innovation, ranking 3rd in the "2025 Chongqing Private Enterprises Technology Innovation Index Top 100" and 4th in the "2025 Chongqing Private Enterprises R&D Investment Top 50" [1][3] Group 1: Company Achievements - Zhifei Biological has made significant advancements in its R&D projects, particularly in the preventive field, with two vaccines, including a quadrivalent influenza virus split vaccine, launched this year [2] - The company has 34 self-developed projects in the preventive field, with 24 in the application, clinical, or listing application stages [2] - In the therapeutic area, Zhifei has 8 self-developed projects, with 7 in clinical or registration stages, including liraglutide injection awaiting listing application [2] Group 2: R&D Investment and Strategy - Over the past three years, Zhifei Biological has invested more than 6 billion yuan in R&D, reflecting its strong commitment to understanding market demands and technological trends [1][2] - The company follows an innovation strategy of prioritizing independent R&D, supplemented by collaborative R&D and investment incubation, which has laid a solid foundation for its sustainable development [1] Group 3: Future Outlook - Zhifei Biological aims to strengthen its position as an innovation leader, focusing on core technologies and addressing public health needs to contribute to the high-quality development of the biopharmaceutical industry and the construction of a healthy China [3]

Core Insights - The project initiated by the China Cancer Foundation and supported by Merck aims to implement a comprehensive cervical cancer prevention program in low-resource areas of China, starting in Shanxi Province [1][4] - Merck has donated a total of 81,000 doses of HPV vaccines to the China Cancer Foundation, which will be distributed for free vaccination of eligible middle school girls in various provinces [1][2] - The project is significant for reducing the burden of HPV-related diseases and is aligned with China's goal of eliminating cervical cancer as part of the Healthy China initiative [1][4] Group 1: Project Implementation - The cervical cancer prevention project officially launched on December 29, 2023, after nearly six months of preparation, including training healthcare personnel and conducting surveys [1][4] - The project specifically targets middle school girls, as vaccination at a younger age is believed to elicit a better immune response and provide more effective protection [3][4] - The initiative is part of a broader strategy to address the rising incidence of cervical cancer in China, particularly among younger women [2][3] Group 2: Public Health Context - HPV infection is a major health threat for women in China, with the country reporting the highest number of cervical cancer cases globally in 2022 [2] - The World Health Organization has emphasized the importance of HPV vaccination as a key preventive measure against cervical cancer, which is increasingly recognized as a public health issue in China [2][3] - The project aligns with the WHO's global strategy to accelerate the elimination of cervical cancer and China's own action plan for 2023-2030 [2][4]

公告，智飞生物公司由控股子公司重庆宸安生物制药有限公司研发的德谷门冬双胰岛素注射液（CA508 注射液）获得了Ⅲ期临床试验总结报告。宸安生物研发的德谷门冬双胰岛素注射液（CA508注射液）在 有效性和安全性上与原研药德谷门冬双胰岛素注射液（诺和佳®）相当，符合《治疗糖尿病药物及生物 制品临床试验指导原则》对有效性与安全性评价的设计要求。截至本公告披露日，经查询国家药品监督 管理局网站，除原研药外，国内有1家企业的德谷门冬双胰岛素注射液获批上市。 ...

市场方面，国内目前除原研药外仅1家企业同类产品获批。若未来CA508注射液获批上市销售，将进一 步夯实公司"预防&治疗"一体化布局，强化市场地位与行业竞争力。 作为新一代基础餐时双胰岛素制剂，CA508注射液由德谷胰岛素与门冬胰岛素组成，可双重控制基础与 餐后血糖，保障降糖效果的同时显著降低低血糖风险。该制剂为澄清溶液，每日注射1-2次且无需混 匀，操作便捷，能提升患者用药依从性。 本次Ⅲ期临床试验由北京大学人民医院牵头，联合40家国内研究中心开展，采用多中心、随机、开放、 平行对照设计，聚焦胰岛素治疗效果不佳的2型糖尿病患者。结果显示，CA508注射液在有效性、安全 性上与原研药（诺和佳®）相当，符合相关指导原则要求，为注册申报提供核心依据。 12月29日，智飞生物发布公告，其控股子公司宸安生物研发的德谷门冬双胰岛素注射液完成Ⅲ期临床试 验并取得总结报告，标志着公司在代谢类疾病治疗领域获关键突破，为后续上市申报奠定基础。 糖尿病是高发慢性代谢性疾病，2型糖尿病占我国病例90%以上，并发症可累及多器官，致残致死率 高，临床对有效治疗药物需求迫切。CA508注射液为治疗用生物制品，适应症为成人2型糖尿病。 责任 ...